ArticleJournal of medical Internet research2025
Online Availability of Diamond Shruumz Before and After FDA Recall Initiation: Qualitative Assessment and Simulated Test Purchasing.
Article in Journal of medical Internet research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mystery shopper assessments of cannabis retailer practices and regulatory compliance in five U.S. states, 2025.Drug and alcohol dependence · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Background: Reports of hospitalization associated with Diamond Shruumz-branded mushroom-containing products in October 2024 led to a manufacturer's recall that restricted the sale, distribution, and accessibility of this new and emerging psychoactive product. Objective: This study seeks to assess the continuing online availability of a mushroom-containing edible product in a diverse e-commerce landscape, specifically aiming to identify and characterize its online availability before and after recall initiation. Methods: A retrospective online market surveillance of Diamond Shruumz products using structured and automated search queries was employed to identify online product marketing and availability. Online surveillance included the monitoring of multiple social media platforms, cannabis e-commerce websites, and search engine queries between June 22 and June 27, 2024, immediately preceding the manufacturer-initiated recall. Post-recall simulated purchases were then conducted on July 12, 2024, on platforms, websites and domains identified as continuing to actively market and sell the products through online product listings. Results: Prior to product recall, a total of 4117 product listings across 1600 (38.86%) social media posts and user-generated comments, 11 (0.27%) cannabis e-commerce websites, and 2509 (60.94%) hyperlinks from internet search queries were generated for further content analysis. Review of online sources revealed 49 social media posts, 8 e-commerce shops, and 67 domains that were identified as actively marketing and selling products prior to recall. Post-recall, we identified 45 (67.16%) remaining domains that continued to market the product from these different online sources. Simulated purchases revealed that 15 (33.33%) domains successfully transacted test purchases and 30 (66.66%) transactions failed because of account verification or payment failure. Conclusions: The Diamond Shruumz recall exemplifies the ongoing challenge of unknown consumer harm associated with new and emerging substances marketed and sold on the internet, which is especially concerning as these products appeal to younger audiences with a variety of edible flavored products. While a recall was initiated and products became unavailable, our study found that post-recall online vendors continued to market and sell the products. This indicates that there are ongoing challenges to effectuate recalls and online enforcement in a diverse e-commerce landscape that can rapidly bring new and novel psychoactive substances to the market.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.